Northern Europe Keeps Up The Pressure On Biosimilar Infliximab Switching
This article was originally published in Scrip
Executive Summary
Northern European efforts to boost the use of biosimilar infliximab rather than Janssen's Remicade are gathering pace, with the Norwegian NOR-SWITCH study having been extended by 26 weeks to complete the switch from Remicade to Celltrion's biosimilar, Remsima, and a number of similar studies being conducted by both industry and non-commercial sponsors in the Netherlands.
You may also be interested in...
Remsima Stars In Orion Pharma’s First Half
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
Remsima Stars In Orion Pharma’s First Half
Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.